MapLight Therapeutics, Inc. (NASDAQ:MPLT) disclosed an insider sale by Jonathan Gillis, its Chief Accounting and Administrative Officer and Principal Accounting Officer. On April 15, 2026, Gillis sold 3,590 shares of the company’s voting common stock for approximately $95,529.
The shares were sold at a weighted average price between $26.6045 and $26.6093. The filing indicates the disposition was executed to meet statutory tax withholding obligations that arose when restricted stock units vested.
After completing the sale, Gillis is reported to directly hold 251,054 shares of MapLight Therapeutics common stock. That total includes 121 shares he acquired under the company’s stock purchase plan on March 31, 2026.
Analyst coverage and program milestones
MapLight has also attracted attention from equity analysts in recent coverage. TD Cowen initiated coverage on the company with a buy rating, focusing on MapLight’s work on treatments for central nervous system and neuropsychiatric disorders. TD Cowen’s commentary singles out ML-007C-MA as the lead program directed at schizophrenia, and cites an expected Phase II data readout in the third quarter of this year.
Stifel has likewise reiterated a buy rating and maintained a $28.00 price target on the company following the firm’s fourth-quarter update. Stifel noted that the Phase II data for ML-007C-MA remains on track for a topline readout in the third quarter of 2026.
In its assessment, Stifel emphasized interest in the M1/M4 mechanism of action, which the note describes as having been de-risked by Cobenfy. The firm said it will be watching for confirmation of efficacy in the Phase II results, along with any potential differentiation in tolerability, safety, or the possibility of once-daily dosing.
These analyst actions and commentary signal ongoing market attention to MapLight’s clinical timeline and the potential implications of ML-007C-MA’s Phase II readout for the company’s development trajectory.